Patrick Daly

DocwireNews

According to researchers led by Pier Mannuccio Mannucci, the data on rates of bleeding outcomes in patients with congenital hemophilia A without inhibitors on factor VIII (FVIII) replacement agents are unclear. Mannucci and colleagues performed a systematic review and meta-analysis on FVIII-containing products as a prophylactic treatment in hemophilia A without inhibitors.Their report, published in&nbsp;Haemophilia, concluded that patients with hemophilia A without inhibitors on FVIII treatments still experience bleeding outcomes, and that alternative treatments not based on factor products or gene therapies are needed for this population.Mannucci and colleagues also suggested &ldquo;it would be beneficial to standardize the measures used in assessing bleed rates across trials to enable accurate comparisons to be made between different treatments, especially as new therapies become more prevalent.&rdquo;<h2>Unacceptable Outcomes for Congenital Hemophilia A</h2>The investigators reviewed 5548 online records and enrolled 58 reports in the meta-analysis, of which 48 were interventional and 10 were observational. Authors calculated the pooled estimated mean annualized bleeding rate (ABR), annualized joint bleeding rate (AJBR), and proportion of patients with zero bleeding events by trial type.<table border="1">
<tbody>
<tr>
<td width="180">

</td>
<td style="text-align: center;" width="180">
ABR
</td>
<td style="text-align: center;" width="180">ABJR</td>
<td style="text-align: center;" width="180">
Zero bleeding events
</td>
</tr>
<tr>
<td style="text-align: center;" width="180">Interventional</td>
<td style="text-align: center;" width="180">3.4 (95% CI, 3.0-3.7)</td>
<td style="text-align: center;" width="180">2.0 (95% CI, 1.6-2.5)</td>
<td style="text-align: center;" width="180">38.5% (95% CI, 33.1-43.9)</td>
</tr>
<tr>
<td style="text-align: center;" width="180">Observational</td>
<td style="text-align: center;" width="180">4.8 (95% CI, 4.0-5.5)</td>
<td style="text-align: center;" width="180">2.6 (95% CI, 2.1-3.2)</td>
<td width="180">
21.8% (95% CI, 19.9-47.5)
</td>
</tr>
</tbody>
</table>The study&rsquo;s authors theorized the improved results seen in clinical trials might be explained by improved compliance due to greater physician oversight or enrollment bias. They suggested the outcomes reported in clinical trials may not be achievable in diverse real-world patients with congenital <a href="https://www.docwirenews.com/post/new-inhibitor-for-heart-failure-treatment-avoids-anemia">hemophilia A</a> without inhibitors.Additionally, there was a large variation in mean effect sizes reported for ABR, AJBR, and proportion of patients with zero bleeding events between patient populations and subgroups. The report noted there was potential reporting bias for ABR and ABJR data in both interventional and observational studies.Mannucci and colleagues felt there was an unmet need for alternative treatment options in patients with congenital hemophilia A without inhibitors on FVIII therapies and suggested their analysis identified &ldquo;inconsistencies and flaws in how bleed data are currently gathered and calculated.&rdquo;Related: <a href="https://www.docwirenews.com/post/simoctocog-alfa-effective-as-first-treatment-for-hemophilia-a">Simoctocog Alfa Effective as First Treatment for Hemophilia A</a>

Sara Nunnery, MD, MSCI

Reclassifying HER2: What Oncologists Need to Know About HER2-Low and -Ultralow Breast Cancer

HER2 Breast Cancer

Jeffrey Perl, MD

Joel M. Topf, MD, FACP

Thoughts From the 2025 Lazarus Award Winner

NKF Spring Clinical Meetings 2025

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

Latest News

Congenital Hemophilia A Trials and Bleeding Outcomes Both Lacking

Hemophilia

New treatments are needed for patients with congenital hemophilia A without inhibitors on FVIII treatments, and clinical trial data on bleeding rates are flawed, analysis suggests.

Congenital Hemophilia A Trials and Bleeding Outcomes Both Lacking 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe